Grafa News and Videos — Page 373

Destination XL Group (NASDAQ:DXLG) filed a preliminary proxy statement with the SEC regarding its pending merger agreement with FBB Holdings I, also known as FullBeauty.

Dynex Capital (NYSE:DX) reported second-quarter economic return of $0.81 per common share and book value of $12.90 per share as of June 30, 2026.

Halozyme Therapeutics (NASDAQ:HALO) announced a global collaboration and license agreement with Incyte (NASDAQ:INCY) to develop subcutaneous formulations of INCA033989.

Nuvation Bio (NYSE:NUVB) reported updated long-term Phase 2 data for safusidenib in chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant glioma.

VERAXA Biotech (NASDAQ:VRXA) received Scientific Advice from Germany’s Paul-Ehrlich-Institute on the biological rationale and non-clinical development plan for its lead BiTAC-TCE programme.

Dyne Therapeutics (NASDAQ:DYN) received FDA acceptance of its Biologics License Application for z-rostudirsen, an investigational treatment for Duchenne muscular dystrophy amenable to exon 51 skipping.

Magnolia Oil & Gas (NYSE:MGY) agreed to acquire WildFire Energy for approximately $4.06 billion, including WildFire’s debt, expanding its South Texas oil and gas position.

Immunome (NASDAQ:IMNM) dosed the first patient in a Phase 1 trial of IM-3050 for FAP-expressing advanced solid tumours.

IREN (NASDAQ:IREN) raised its year-end 2026 AI Cloud annualized run-rate revenue (ARR) target to over $4 billion, up from its previous target of $3.7 billion.

Highway Holdings (NASDAQ:HIHO) reported first-quarter fiscal 2027 revenue of approximately $2 million, representing a 29.2% increase compared to the same period last year.